On June 2, 2022, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced that it has formally submitted a First-in-Human (FIH) clinical trial application for ESG206 to the Bellberry Human Research Ethics Committee (Bellberry HREC) in Australia, for the treatment of malignant B cell lymphoma and chronic lymphocytic leukemia.

The "Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ESG401 in Patients with Locally Advanced/Metastatic Solid Tumors" (Study Number: ESG401-101), sponsored by Shanghai Escugen Biotechnology Co., Ltd. ("Escugen"), has been successfully launched and is currently recruiting participants. The study has received approval from the National Medical Products Administration (Clinical Trial Notification Number: 2021LP01074) and will recruit participants at multiple top-tier hospitals across the country.